Precision Medicine for Tailored Treatments
Precision medicine is tailored to the individual patient instead of a one‐drug‐fits‐all model. It has been very successful in the area of inhibitors targeting BRCA-mutant cancers with PARP inhibitors and specific oncogenic kinases, such as EGFR, BRAF, ALK and BCR-ABL. There is tremendous potential for more precision medicine. By finding sensitive cancer subtypes and developing selective therapeutics, the therapeutic efficacy of a drug or drug combination can be enlarged, leading to a much greater chance of success in clinical trials.
Our Goal is Discovering Precision Medicines and Finding a Mechanistic Hypothesis Before Entering the Clinic
We have generated technologies that focus on robust in vitro assays to identify the mechanism of drug candidates. Our technologies provide in vitro proof of concept which facilitates the design of in vivo studies and clinical trials.